论文部分内容阅读
目的探讨注射用唑来膦酸5 mg对原发性骨质疏松症患者的临床疗效。方法选取2011年6月至11月住院期间53例原发性骨质疏松症患者,所有患者均初次诊断为原发性骨质疏松症,未曾行任何抗骨质疏松治疗,同时排除其他骨代谢性疾病或药物影响,随机分为研究组28例,平均年龄60.4岁,给予唑来膦酸5 mg,静脉滴注30 min,同时口服钙尔奇D600 mg/d及阿尔法D30.25μg/d;对照组25例,平均年龄61.2岁,给予口服钙尔奇D600 mg/d及阿尔法D30.25μg/d,治疗时间为1年。采用双能X线骨密度仪(DEXA)测定两组治疗前后的L1-4、股骨颈、Ward’s三角区骨密度值。结果排除对照组中2例患者失访外,研究组骨密度增幅程度均显著高于对照组(P<0.05)。4例患者在注射唑来膦酸后出现发热、头痛及流感样症状,给予非甾体类抗炎药(NSAIDs)对症治疗后4例患者均在3 d内缓解,未见其他不良反应。结论唑来膦酸注射液5 mg可明显提高原发性骨质疏松症患者的骨密度,且不良反应可耐受,在原发性骨质疏松症患者中值得推广应用。
Objective To investigate the clinical efficacy of 5 mg zoledronic acid injection in patients with primary osteoporosis. Methods Fifty-three patients with primary osteoporosis during hospitalization from June 2011 to November 2011 were selected. All patients were diagnosed as primary osteoporosis for the first time without any anti-osteoporosis treatment and other bone metabolism was excluded The patients were randomly divided into study group (n = 28) with average age of 60.4 years. Patients were given 5 mg zoledronic acid and intravenously for 30 min. The patients were also given oral Dicelosine D600 mg / d and alpha D30.25 μg / d. Control group of 25 patients, mean age 61.2 years old, given oral calcium Erqi D600mg / d and alpha D30.25μg / d, treatment time was 1 year. The BMD values of L1-4, femoral neck and Ward’s triangle before and after treatment were measured by dual energy X-ray absorptiometry (DEXA). Results Excluding 2 patients in the control group, the increase of BMD in the study group was significantly higher than that in the control group (P <0.05). Four patients developed fever, headache and flu-like symptoms after injecting zoledronic acid. All four patients were relieved within 3 days after symptomatic treatment with NSAIDs and no other adverse reactions were found. Conclusion Zoledronic acid injection 5 mg can significantly improve the bone mineral density in patients with primary osteoporosis, and adverse reactions can tolerate, in patients with primary osteoporosis worth promoting.